Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Emir CELİK"'
Autor:
Emir Celik, Tuğçe Emiroğlu, Hakan Yavuzer, Rabia Bağ Soytaş, Alper Döventaş, Damla Ünal, Veysel Suzan, Osman Faruk Bayramlar, Pınar Arman, Deniz Suna Erdinçler, Serkan Sürme
Publikováno v:
Sakarya Tıp Dergisi, Vol 11, Iss 2, Pp 238-245 (2021)
Objective: The aim of our study is to analyze the patients followed with the diagnosis of pneumonia in our geriatric clinic and discuss the effect of vaccination on prognosis by questioning the status of the vaccination before infection. Materials an
Externí odkaz:
https://doaj.org/article/57c5de76ff1b460e8deddc3915e9b309
Autor:
Nilay Sengul SAMANCİ, Emir CELİK, Ezgi DEGERLİ, Melih KASAP, Kerem ORUC, Sahin BEDİR, Sumeyra DERİN, Nihan SENTURK OZTAS, Burc Cagrı POYRAZ, Zeynep Hande TURNA, Fuat Hulusi DEMİRELLİ
Publikováno v:
Namık Kemal Tıp Dergisi, Vol 8, Iss 2, Pp 138-144 (2020)
Aim:Sleep disorders are one of the most common problems in patients with malignancy and they severely decrease the quality of life. We sought to investigate the frequency of sleep disturbances, its quantity, quality and possible correlation with rela
Externí odkaz:
https://doaj.org/article/4ab956db61934316b6cc2b3a7bf179c0
Autor:
Nilay Samanci, Emir Celik
Publikováno v:
Contemporary Oncology, Vol 24, Iss 1, Pp 17-28 (2020)
Externí odkaz:
https://doaj.org/article/1ee662377dde4dca96f170412957f1ee
Autor:
Pınar Gursoy, Ali Murat Tatli, Dilek Erdem, Erdem Goker, Emir Celik, Nebi Serkan Demirci, Abdullah Sakin, Muhammed Mustafa Atci, Ertuğrul Bayram, Tuğba Akın Telli, Burak Bilgin, Ahmet Bilici, Baran Akangunduz, Sevinç Balli, Ahmet Demirkazik, Fatih Selçukbiricik, Serkan Menekse, Eyyüp Cavdar, Akın Ozturk, Esma Türkmen Bekmez, Serdal Turhal, Sadettin Kilickap, Hasan Çağrı Yildirim, Başak Oyan, Asude Aksoy, Fatma Paksoy Turkoz, Engin Kut, Nuran Katgi, Teoman Sakalar, Murat Akyol, Halil İbrahim Ellez, Atakan Topcu, Atike Pınar Erdoğan, Kezban Nur Pilanci, Engin Hedem, Hacı Arak, Nadiye Akdeniz, Özkan Alan, Burcu Yapar, Deniz Nart, Perran Fulden Yumuk
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 149:865-875
Objectives: To compare the survival of first- and second-generation tyrosine kinase inhibitors (TKIs) in patients with rare EGFR exon 18 and exon 20 mutation-positive non-small cell lung cancer (NSCLC). Materials and methods: We retrospectively evalu
Autor:
Mehmet Karadag, Aysegul Akkan Suzan, Nilay Sengul Samanci, Fuat Demirelli, Hakan Yavuzer, Alper Döventaş, Emir Celik, Serdar Sahin, Muhammed Samil Aslan, Nebi Serkan Demirci, Veysel Suzan
Publikováno v:
European Geriatric Medicine. 13:267-274
Introduction In 2019, The EWGSOP2 group made updates on the definition and diagnosis of sarcopenia. The aim of this study is to determine the possible risk factors for chemotherapy dose-limiting toxicity (DLT). Methods Newly diagnosed gastrointestina
Autor:
Nilay Sengul Samanci, Muhammed Samil Aslan, Emir Celik, Nebi Serkan Demirci, Fuat Hulusi Demirelli, Mehmet Karadağ, Yasemin Cakan Celik, Veysel Suzan
Publikováno v:
Namık Kemal Tıp Dergisi. 9:84-90
Autor:
Sadettin Kilickap, Mutlu Hizal, Ahmet Gulmez, Okan Avci, Burak Yasin Aktas, Havva Yesil Cinkir, Emir Celik, Mustafa Gürbüz, Berna Oksuzoglu, Ali Murat Tatli, Gulhan Ipek Deniz, Cihan Erol, Erdem Sen, Fulden Yumuk, A İlhan, Şebnem Yücel, Semra Paydas, Ozkan Alan, Engin Kut, Fatih Karatas, Atakan Demir, Murat Ayhan, Bulent Yalcin, Halil Taskaynatan, Tugba Basoglu, Serkan Menevse, Deniz Tataroğlu Özyükseler, Nadiye Akdeniz, Sinan Koca, Mustafa Karaagac, Burak Bilgin, Didem Sener Dede, Mehmet Ali Nahit Sendur, Muhammed Bulent Akinci, Izzet Dogan, Ahmet Demirkazik, Teoman Sakalar
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 147:2145-2152
The new second-generation tyrosine kinase inhibitors (TKIs) have superior survival outcome and worse toxicity profile when compared with first-generation TKIs according to the results of clinical trials. However, there are limited studies that invest
Autor:
Fuat Demirelli, Nilay Sengul Samanci, Duygu Ilke Cikman, Nihan Şentürk Öztaş, Sahin Bedir, Emir Celik, Ezgi Degerli, Kerem Oruc, Nebi Serkan Demirci, Mehmet Karadag, Sumeyra Derin
Publikováno v:
Journal of Oncology Pharmacy Practice. 27:1665-1673
Introduction Erlotinib is an effective treatment option for EGFR-mutant non-small cell lung cancer. It is important to predict patients who will respond better to erlotinib. We designed this study to investigate the effect of renal insufficiency (RI)
Autor:
Emir Celik, Sahin Bedir, Nebi Serkan Demirci, Omer Bagcilar, Kerem Oruc, Ela Bicki, Burak Caglar Erol, Nilay Sengul Samanci, Ezgi Degerli, Sumeyra Derin, Fuat Demirelli
Publikováno v:
Melanoma Research. 30:477-483
This study aimed to assess whether dabrafenib/trametinib and vemurafenib/cobimetinib treatments are associated with a change in skeletal muscle area (SMA) and total fat-free mass (FFM) assessed by computed tomography (CT), and to compare the efficacy
Autor:
Yakup Iriagac, Eyyup Cavdar, Kubilay Karaboyun, SeherYildiz Tacar, FatmaNihan Akkoc Mustafayev, Emir Celik, Okan Avci, SadiKerem Okutur, Lokman Koral, NebiSerkan Demirci, Alpaslan Ozgun, ErdoganSelcuk Seber
Publikováno v:
Journal of Cancer Research and Therapeutics.